Dr. Randolph Seidler received his training in veterinary medicine from the Ludwig-Maximilians University (LMU) in Munich, Germany. He did his Ph.D. research at The Ohio State University in Columbus, Ohio, and the LMU in the area of cardiac physiology and pharmacology. He joined Boehringer Ingelheim’s human pharma R&D conducting research in the area of general pharmacology and cardiovascular drug discovery in Biberach, Germany and in Ridgefield, Connecticut. During this time, Dr. Seidler headed a group of scientists in the area of heart failure and myocardial infarction research and led several drug discovery projects that progressed to clinical development. In July 2007, he was appointed head of Global Department R&D at Boehringer Ingelheim’ s Animal Health (BIAH) business, overseeing global Research and Development of pharmaceuticals and vaccines, Regulatory Affairs, Pharmacovigilance and Quality Assurance. Since 2017 he has been appointed as Head of Global Business Development and Licensing for BIAH.
Clint Lewis, Executive Vice President and President of International Operations, Zoetis
Clint Lewis is executive vice president and president of International Operations at Zoetis. In this role, he oversees the management of the livestock and companion animal business markets outside the United States.
Mr. Lewis previously served as president, U.S. Operations at Zoetis and in the Pfizer Animal Health organization. He joined Pfizer Animal Health in 2007. Mr. Lewis joined Pfizer in 1988 as a sales representative in Long Island, N.Y., and has held positions of increasing responsibility in several areas across various commercial operations dedicated to human health prior to joining animal health, including vice president and general manager of Pfizer’s U.S. Anti-Infectives/HIV business unit.
In 2011, Mr. Lewis was elected chairman of the Animal Health Institute (AHI) for the 2011-12 term. A member of AHI since 2007, Mr. Lewis previously served as AHI vice chair for the 2009-2010 term. AHI is the trade association for the animal health industry in the U.S. advocating on various issues important to the industry, including efficient and effective regulatory and approval processes by the U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA), and the Environmental Protection Agency (EPA).
Mr. Lewis holds a bachelor’s degree in biology from Fairfield University and a Master of Business Administration in marketing from Fairleigh Dickinson University.
Mr. McCarthy is now in his 7th year at Henry Schein, Inc. He is currently the Company’s President, Global Animal Health Group, as well as a member of Henry Schein’s Executive Management Committee. Mr. McCarthy oversees Henry Schein’s animal health business, which spans 24 countries including the United States, Australia, New Zealand, Canada, China, Malaysia, Brazil and 17 countries in Europe. Before assuming his current position, Mr. McCarthy held key roles at Henry Schein with increasing responsibilities, including President, Henry Schein Animal Health, Europe, and President, Henry Schein Animal Health, International.
Prior to joining Henry Schein, Mr. McCarthy worked at Schering-Plough Animal Health (now Merck Animal Health), serving as Senior Director, Global Operations and General Manager, China. Mr. McCarthy also worked at Wyeth/American Cyanamid for 14 years, helping to grow the human pharmaceutical business. Mr. McCarthy holds a degree in Applied Biology from the University of Hertfordshire in the U.K., and previously has served as a Member of the Board of the International Federation for Animal Health Europe, and the International Association Executive Animal Health Study Center, CEESA, based in Belgium. Mr. McCarthy is also a graduate and member of the Chartered Institute of Marketing (CIM), which is located in the U.K.
Carel du Marchie Sarvaas is Executive Director of Health for Animals, the global animal medicines association. Health for Animals represents the top 10 global companies – Bayer, Boehringer Ingelheim /Merial, Ceva, Elanco, Merck/MSD, Phibro, Vétoquinol, Virbac, Zoetis – and 29 national associations. The companies and associations represent 85%+ of the global market for animal vaccines, antibiotics, paraciticides and other animal health products.
Carel has been a senior government affairs and communications professional for 25 years. He joined Health for Animals in 2014 after holding the position of Director at the BioTechnology Association EuropaBio. Prior to that, Carel worked at international consultancies and think tanks in Brussels and Washington, DC, representing clients in the food, agriculture, chemicals, nanotech and biotech sectors. He holds degrees from the University of Leiden and the Johns Hopkins University.
Dr. Tye Perrett received his Bachelor of Science in Agriculture from the University of Alberta in 1995, and his Doctor of Veterinary Medicine from the Western College of Veterinary Medicine in 1999. After graduation Tye joined the Lethbridge Animal Clinic as an associate and then a partner in the practice. In 2004 he became associated with Feedlot Health Management Services Ltd. and is currently a Managing Partner. He has been a director as well as president of both the Western Canadian Association of Bovine Practitioners, and the Canadian Association of Bovine Veterinarians. Tye currently serves on Council of the Alberta Veterinary Medicine Association. In 2012 Tye was the recipient of the 2012 Boehringer-Ingelheim Western Canadian Association of Bovine Practitioners Veterinarian of the Year Award. Tye, Tanya and their 5 boys very much appreciate living on their small acreage just outside of Okotoks where they spend time enjoying their horses and are active in church and sports activities.
Lalit Gaur is Head of Global Business Development and Licensing for Vetoquinol, one of the leading animal health pharmaceutical company. In this role, Lalit is responsible for new product portfolio growth. He has 20 years of progressive experience in business development and licensing function across many segments of healthcare and bio-pharmaceutical industries.
He started his career in human medical diagnostics, and gained experience in platform technologies to consulting to life science research to animal diagnostics and pharmaceuticals. Prior to joining Vetoquinol, Lalit was founder and president of LG Biopartners, LLC, a boutique firm providing consulting services and helping clients build value through strategic options. Before that Lalit was Director of BD&L for Novartis, leading their business development in North America for the animal health division. He joined Novartis from IDEXX, world leader in animal health diagnostics, where he led the licensing and strategic partnerships function.
He holds an MBA in Finance from Rice University in Houston, Texas and an MS in Molecular Biology from Texas A&M University in College Station
Adam Little works at the intersection of accelerating technologies and veterinary medicine to help solve some of our world’s biggest problems. His entrepreneurial approach to global animal health creates more opportunities for veterinarians to tackle challenges ranging from companion animal medicine to food security and infectious disease spread. As a champion for the evolution of his profession, Little sees a near future in which real-time, personalized medicine for each animal on this planet is possible. And he believes veterinarians are the drivers of that future, leading global change that will benefit every man, woman, child, and animal.
Little found his passion during veterinary school, identifying a number of challenges in the veterinary space for both those providing and receiving care, and became motivated to rethink how we can provide the best care possible. He went on to lead the team creation of the first IBM Watson project in the veterinary space, which grew to nearly 100 people. As founder and president of Exponential Vet Inc.—a consultancy create to help bridge the gap between early-stage technology companies and animal health—he works with clients in the areas of telemedicine, point of care diagnostics, sensors, and data analytics.
He recently accepted a position as a faculty member at Texas A&M College of Veterinary Medicine & Biomedical Sciences where he will serve as Director of Innovation and Entrepreneurship. Little holds a graduate degree from Ontario Veterinary College and completed the Graduate Studies Program at Singularity University. He serves on the Board of Directors with Veterinarians Without Borders and the Catalyst Council, and is a consultant with Exponential Organizations.
Stephen Murray is a dairy veterinarian from New Zealand who landed in the Netherlands, Ireland and Canada before his current role in the U.S. with Merck Animal Health. Prior to this role, Stephen served as General Manager of Merck Canada. He has worked in a variety of roles including GM, Global Marketing, SFE, Training, CRM, and Digital / Multi-channel Marketing. His new focus is on Innovation in the Animal Health world.
Heather Bessoff, DVM, Director of Business Development, Sales and Marketing, EpiBiome
Dr. Heather Bessoff is the Director of Business Development, Sales and Marketing of EpiBiome, a South San Francisco-based venture-backed precision microbiome engineering company whose mission is to develop the next-generation of antibacterials that will protect humanity against the rising global threat of antibiotic resistance.
Dr. Bessoff is a graduate of the University of Wisconsin School of Veterinary Medicine and spent many years in dairy practice and as a global dairy herd management consultant. She has worked for Pfizer, Inc. and Elanco in positions of increasing responsibility in R&D and in their commercial businesses including developing strategies around products, portfolios and new enterprises to improve animal health and starting and running new businesses in genomics and diagnostics. Her goal is to have a significant global impact in providing a safe, healthy and abundant food supply for the world’s growing population.
Charles Hoare is a Managing Director and Head of European Healthcare at Stifel, as well as leading the firm’s global veterinary practice. He has more than 20 years experience in mergers & acquisitions and capital raising for healthcare companies. During this time he has had a particular focus on the animal health sector and has advised most of the major players in the industry (including Zoetis, Boehringer Ingelheim, Elanco, Merial, Ceva, Virbac and Phibro).
Recent transactions include advising Jaguar Animal Health on its merger with Napo Pharmaceuticals and Animal Ethics on its sale of a minority stake to Dechra Pharmaceuticals. Additionally (while at a previous, unaffiliated, firm) he advised Zoetis on the sale of a range of non-core assets, Virbac on the acquisition of Sentinel, Pharmaq on its sale to Permira and Lohmann on its sale to Elanco.Stifel also led the IPOs of Aratana and Trupanion.
Bob Fountain has a B.A. Degree from the University of Pennsylvania and an M.B.A. Degree from the Wharton School of Business at the University of Pennsylvania. He was a member of the University of Pennsylvania’s Rowing Team that won 3 National Championships and represented the USA in the 1968 Olympics.
He began his 48-year animal health industry career with Merck & Company’s Merck AgVet Division (now Merial Ltd.) where he had responsibility for the Australian animal health business. Later he was responsible for international business development and was located at Merck AgVet’s New Jersey, USA headquarters. He then moved to Pfizer Inc. with management responsibility for Pfizer’s animal health business in Japan and Asia, based from Hong Kong. He then was assigned to Nairobi, Kenya and managed Pfizer’s animal health business for Africa and Middle East business. His last assignment at Pfizer Animal Health was in New York as Vice President of Marketing for the USA business.
He founded Fountain Agricounsel in 1992 and went into partnership with Dr. Duane Thurman as Fountain Agricounsel, LLC in 1996. He resides in Stonington, CT, USA. Fountain has undertaken dozens of photographic assignments with National Geographic and is an avid sailor.
Coming from South Africa, where traditional advertising barely existed and brands had to get their hands dirty and actively engage their audience, Claire Lamont saw that missing in the marketing industry when she moved to North America. In 2003, she co-founded smak, an agency specializing in creating authentic brand experiences. It was conceived from her frustration at the brand noise shouting from billboards and blinking lights rather than creating genuine engagements with its target audience.
At 24, she quickly learned the ropes of what a great leader needs to be. From the ground up, she built a team with the notion of doing it different and steered a cross-country team to stay true to its own brand’s culture and values, while introducing its clients’ brand values to their target audience. As the co-founder and creative lead of smak, Claire quickly became a thought leader in the industry around “doing it different” and sharing her passion for brand experience on many stages.
She has been recognized as one of Business in Vancouver ’BC’s 40 under 40’, as well as one of Marketing Magazine’s National ‘Ones to Watch, 30 under 30’ in 2008. Claire has developed award-winning & cutting-edge campaigns for clients, such as MINI Cooper, Telus, Kleenex and Nando’s and will lead a half-day workshop for companies.
Dr. Rotondo is a veterinarian, speaker, consultant and entrepreneur who has collaborated with a variety of groups and organizations to increase business and personal performance. He holds a DVM degree from Cornell University and MBA from Rensselaer Polytechnic Institute. Dr. Rotondo has been recognized as an expert in practice management and the dynamics associated with successful practices and businesses. He specializes in effective client communication, customer experience engineering, and consumer insights. He has owned and operated 5 veterinary hospitals in New York and has served on numerous boards within local, state and national veterinary organizations. He served on the Advisory Council to the Veterinary College at Cornell University and was selected as President of the New York State Veterinary Society during its centennial year and was honored as the New York State Veterinarian of the Year. He has held advisory roles for several veterinary pharmaceutical companies, reference laboratories and veterinary corporate ownership groups. And has represented New York State to the AVMA House of Delegates.
Dr. Rotondo has lectured extensively throughout North America and Europe. He recently collaborated and partnered with Dr. Howard Moskowitz, author of the business text “Selling Blue Elephants” (Wharton Press). Together they have created Mind Genomics Advisors, an actionable research organization focusing on empirical consumer insights, whose mission is dedicated to delivering specific, targeted messaging to clients, patients, donors, and consumers. Dr. Rotondo lectures annually at the Wharton Business School and other universities. He resides in historic Saratoga Springs, NY with his wife Jill and their two dogs Lucy and Greta.
Mr. Sun Jinzhong, Vice Chairman, Pulike Biological Engineering Co., Ltd.
Mr. Sun Jinzhong graduated from China agricultural university, with a degree in veterinary medicine. He is vice chairman of Pulike Biological Engineering Co. Ltd., Deputy Director of the National Research Center for Veterinary Medicine, Deputy secretary-general of China animal husbandry and veterinary institute council, China veterinary drug standard committee member, Vice chairman of Henan animal health products association, Director and deputy secretary general of Henan animal husbandry and veterinary institute, and Luoyang biological engineering expert technical committee member.
Pulike is engaged in the research, manufacturing, and commercialization of veterinary bio-products. Pulike is one of the top five veterinary companies operating in China’s domestic market. In 2015, Pulike launched its product on the Shanghai stock market. With the philosophy of “Innovation achieves future”, Pulike was approved to set up a National Research Center for Veterinary Medicine (NRCVM) next to the Department of Science and Technology of the Chinese People Republic of China.
Pulike invests heavily in R & D and has been able to overcome some of the bottlenecks and infrastructural problems for domestic industry development. Pulike adheres to the purpose of “Gold quality, benefits mankind” to follow the development concept of “Innovation achieves future”. It’s high standards of R&D, manufacturing and distributing veterinary products make Pulike one of China’s top brands in animal health products.
Daniel Hurnik, DVM, MSc, Chair, Department of Health Management, Atlantic Veterinary College, UPEI
Dr. Daniel Hurnik is Professor of Swine Health Management and Chair of the Department of Health Management at the Atlantic Veterinary College, UPEI. He holds a Doctor of Veterinary Medicine degree from the University of Guelph, and a Master of Science degree in epidemiology from UPEI. Dr. Hurnik has served AVC as an industry research chair, interim dean, and chair of two departments. He is a founder of the Atlantic Swine Research Partnership Inc.
His research has supported the establishment of two P.E.I. biotech companies, Progressive Bioactives Inc., and Chemaphor Inc. (now Avivagen). He is veterinary consultant to International Genetics PEI Ltd. and International Genetics Ltd., which together market Canadian swine genetics and expertise worldwide. Dr. Hurnik has been a director on the Canadian Swine Health Board and the Canadian Centre for Swine lmprovement, which manages Canada’s national swine genetics program.
He has advised the industry on the development of a national swine farm-level biosecurity standard and a quality assurance program, in conjunction with the Canadian Veterinary Medical Association and the Canadian Pork Council. He has been a technical advisor to the federal porcine circovirus associated diseases task team and the national swine traceability program. He has been a consultant to the World Bank on management of African swine fever in Eastern Europe, and co-authored a biosecurity guide for pig production for the World Bank, FAO, and the World Health Organisation for Animal Health.
Daniel Ferguson, Writer/Director
Daniel Ferguson is a Montreal-based writer/director of documentaries and IMAX films. His last IMAX film, JERUSALEM, won awards for Best Film and Best Cinematography at the 2014 Giant Screen Cinema Association Achievement Awards and has been seen by over 5 million people. His recent feature documentary, Last of the Elephant Men, won 4 Gemini awards and was nominated for the Green Oscar at the Cinema for Peace awards in Berlin. For the past 3 years, he has been researching and filming some of the world’s most exceptional working dogs for his new IMAX 3D film, Superpower Dogs.
Daniel has worked in over 40 countries and has also made films for History Television, France Television, the National Wildlife Federation, National Geographic Channel, Discovery Channel and the Smithsonian Institution. He serves on the boards of the Giant Screen Cinema Association and the Alter-Ciné Foundation, a Montreal-based fund offering grants to documentary filmmakers in Africa, Asia and Latin America. He graduated McGill University in 1996 with a Joint Honours degree in History and Religious Studies and has a diploma from Vancouver Film School.